Active, not recruitingPhase 2NCT07523763
Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer
Studying Constitutional mismatch repair deficiency syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Blokhin's Russian Cancer Research Center
- Intervention
- Nivolumab(drug)
- Enrollment
- 30 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- N.N. Blokhin NMRCO, Moscow, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07523763 on ClinicalTrials.govOther trials for Constitutional mismatch repair deficiency syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07450612Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease DetectionSan Raffaele University
- RECRUITINGNANCT06215677Neoadjuvant Immunotherapy for T4 dMMR Colon CancerPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT05729646Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaYu jiren
- ACTIVE NOT RECRUITINGPHASE2NCT02983578Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02359565Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaNational Cancer Institute (NCI)
See all trials for Constitutional mismatch repair deficiency syndrome →